At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
ocriplasmin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of DME.
In Brief
A Phase 2 clinical trial evaluating ocriplasmin and Sham injection for Diabetic Macular Edema. Completed, enrolled 51 participants across 15 sites in 6 countries.
Detailed Summary
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesBelgium, Germany, Italy, Netherlands, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionJan 2010
Study CompletionMar 2010
TodayJul 2026
First PostedDec 18, 2006
Enrollment StartDec 1, 2006
Primary CompletionJan 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.5 years ago
Interventions
ocriplasmindrug
Intravitreal injection, single administration
Sham injectionother
Sham intravitreal injection